Patient Survey on New Therapy: Opdivo + Yervoy in combination, for treatment-naïve adult patients with advanced (unresectable or metastatic) melanoma, regardless of BRAF status |
Patient Input Required for Canadian Provincial Drug Review
The Save Your Skin Foundation (SYSF) is currently gathering patient information for a submission to the Pan Oncology Drug Review (pCODR). This submission is important, as it helps patients to have a voice and to contribute to the drug approval process in Canada.
The submission will report on the experiences and opinions of melanoma patients and caregivers regarding Opdivo+Yervoy in combination, for treatment-naïve adult patients with advanced (unresectable or metastatic) melanoma, regardless of BRAF status. This combination therapy is now being reviewed for funding approval in provinces across Canada.
The Pan Canadian Oncology Drug Review, (pCODR) is an evidence-based, cancer drug review process in Canada. The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions. Under the pCODR process, detailed assessments are conducted by a pan-Canadian expert review committee, with opportunities for input by patient advocacy groups, the pharmaceutical industry, clinician-based tumour groups, and the provincial advisory group. For more information, visit www.pcodr.ca.
Through this survey, Save Your Skin collects patient feedback in order to submit and report to pCODR on behalf of melanoma patients. The aim of our submission is to support the approval of financial coverage of these drug therapies for provinces throughout Canada. Effective treatment therapies for metastatic melanoma are limited in Canada, and melanoma patients are in need of equal timely and affordable treatment options.
All information collected by the Save Your Skin Foundation will be compiled and consolidated prior to submission. In order to ensure privacy, individual responses, names, and contact information, will not be identifiable. Patient information will not be shared with any other external organizations, nor will information be shared for any purpose other than this submission. Selected quotes may be used without reference to names or other identifying information.
Thank you very much for contributing your feedback and information related to your experience with this new therapy. Your contribution is vital to improving the access of important treatments for patients throughout Canada and to the approval of funding of these drug therapies.
Thank you,
Kathy Barnard
Save Your Skin Foundation
The submission will report on the experiences and opinions of melanoma patients and caregivers regarding Opdivo+Yervoy in combination, for treatment-naïve adult patients with advanced (unresectable or metastatic) melanoma, regardless of BRAF status. This combination therapy is now being reviewed for funding approval in provinces across Canada.
The Pan Canadian Oncology Drug Review, (pCODR) is an evidence-based, cancer drug review process in Canada. The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions. Under the pCODR process, detailed assessments are conducted by a pan-Canadian expert review committee, with opportunities for input by patient advocacy groups, the pharmaceutical industry, clinician-based tumour groups, and the provincial advisory group. For more information, visit www.pcodr.ca.
Through this survey, Save Your Skin collects patient feedback in order to submit and report to pCODR on behalf of melanoma patients. The aim of our submission is to support the approval of financial coverage of these drug therapies for provinces throughout Canada. Effective treatment therapies for metastatic melanoma are limited in Canada, and melanoma patients are in need of equal timely and affordable treatment options.
All information collected by the Save Your Skin Foundation will be compiled and consolidated prior to submission. In order to ensure privacy, individual responses, names, and contact information, will not be identifiable. Patient information will not be shared with any other external organizations, nor will information be shared for any purpose other than this submission. Selected quotes may be used without reference to names or other identifying information.
Thank you very much for contributing your feedback and information related to your experience with this new therapy. Your contribution is vital to improving the access of important treatments for patients throughout Canada and to the approval of funding of these drug therapies.
Thank you,
Kathy Barnard
Save Your Skin Foundation